Phase III clinical trial of a new biological anticancer drug recombinant human endostatin injection project in Wuzhong, Jiangsu Province is progressing smoothly
-
Last Update: 2020-04-03
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Jiangsu Wuzhong (600200) disclosed in the evening of August 21 that the operating revenue of the company in the first half of the year was 1.531 billion yuan, down 11.18% year on year; the net profit attributable to the shareholders of the listed company was 16.8506 million yuan, down 2.49% year on year; the basic earnings per share was 0.027 yuan As of July 31, 2014, the phase III clinical trial of the "national first class biological anti-cancer new drug recombinant human endostatin injection project" of the company has progressed smoothly It has successively accepted and carried out 402 group case trials in 38 project center hospitals in Beijing, Shanghai, Jiangsu, Guangdong, Fujian, Shandong, Sichuan, Anhui, Jilin, Hunan and other provinces.
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
